Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
Sponsored by EyePoint Pharmaceuticals
In June 2022, a virtual roundtable was convened to discuss how Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg has been integrated into retina practices and can provide an additional treatment option for the long-term control of noninfectious uveitis affecting the posterior segment. The information contained herein is based on that discussion.
